Glenmede Trust’s Tectonic Therapeutic TECX Stock Holding History

Glenmede Trust’s Portfolio TECX Stock Details TECX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-35	Closed	-$6	–	3146
2019 Q3	$6	Buy	+35	New	+$7.92K	﹤0.01%	2582

Other funds holding TECX

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Glenmede Trust's TECX Position: Q4 2019 in Review

Glenmede Trust sold out of Tectonic Therapeutic (TECX) in Q4 2019, closing a stake of 35 shares — an estimated $6 sold.

Glenmede Trust first reported a position in TECX in Q3 2019 and held it in 1 quarter. The position peaked at $6 in Q3 2019. 89 funds tracked by Wall St. Rank hold TECX as of Q4 2019.

Glenmede Trust reported no remaining Tectonic Therapeutic position as of Q4 2019 after selling out during the quarter.
Glenmede Trust sold 35 Tectonic Therapeutic shares in Q4 2019, an estimated $6.
Glenmede Trust first reported a position in Tectonic Therapeutic in Q3 2019 and held it in 1 quarter.
Glenmede Trust's Tectonic Therapeutic position peaked at $6 in Q3 2019.
89 funds tracked by Wall St. Rank held Tectonic Therapeutic as of Q4 2019.

Based on Glenmede Trust's 13F filing for Q4 2019, filed 12 Feb 2020.